A potential spin-off of Cytovia into a stand-alone company pursuing an independent path from Immune would provide several advantages:
- Allows current Immune investors to benefit from two distinct investment opportunities through proportional receipt of shares in Cytovia;
- Enables Cytovia to target new investors attracted to its specific oncology business profile and pursue distinct capital structures and capital allocation strategies; and
- Aligns Cytovia’s resources with its stated goals and tailors its business strategy to best address opportunities within its target market of oncology
“The proposed restructuring strategy recognizes that our two operating divisions have evolved into distinct busine…
Read the full article at: http://www.prnewswire.com/news-releases/immune-pharmaceuticals-announces-corporate-restructuring-300444081.html